SOURCE: CLX Investment Company, Inc.

January 09, 2008 10:58 ET

CLX Investment Company Releases January 2008 Newsletter Highlighting Planned Clinical Trials for Zonda Chlamydia Product

MURRIETA, CA--(Marketwire - January 9, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today released its January 2008 investor newsletter, which highlights the recent announcement of planned clinical trials for Zonda's rapid, point of care Chlamydia product.

A PDF version of the newsletter can be viewed on the company's corporate website at http://www.clxinvestments.com/newsletters.php.

The main newsletter article reviews CLX's recent announcement that Safis Solutions, LLC is preparing to initiate clinical trials for Zonda's rapid point of care test for Chlamydia as part of the process to achieve FDA clearance for the product. CLX anticipates a mid to late first calendar quarter 2008 beginning for the clinical trials for the Zonda Chlamydia product.

Safis Solutions, LLC, an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, was retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.

The newsletter also reviews the recent filing of the company's annual report on Form 10-KSB for the 2007 fiscal year and the Current Report on Form 8-K/A related to its recent acquisition of a majority percentage of Zonda.

"As we work to maximize the potential value of Zonda through our associations with Safis Solutions and American Health Partners and seek additional products and technologies for possible acquisition, licensing and/or distribution relationships, we will continue to communicate with shareholders through regular press releases and monthly newsletters," stated Vera Leonard, president and chief executive officer of the company.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-677-8073
    Email Contact